Skip to main content

Table 3 Odds ratios for lasmiditan treatment versus placebo were similar or greater in the group of patients using preventives than in those not using preventives

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

OutcomeLasmiditan dose (mg)Using preventivesNot using preventivesInteraction p-valueb
n/N (%)Odds ratioa (CI)n/N (%)Odds ratioa (CI)
Pain-free at 2 hPBO23/196 (11.7) 172/867 (19.8)  
5025/104 (24.0)2.2 (1.0, 4.7)134/452 (29.6)1.4 (1.0, 1.9)0.715
10044/175 (25.1)2.5 (1.4, 4.4)265/860 (30.8)1.8 (1.4, 2.2)0.654
20051/167 (30.5)3.3 (1.9, 5.7)321/879 (36.5)2.3 (1.9, 2.9)0.550
MBS-free at 2 hPBO45/189 (23.8) 271/813 (33.3)  
5037/97 (38.1)2.0 (1.1, 3.7)172/415 (41.4)1.3 (1.0, 1.7)0.342
10055/160 (34.4)1.7 (1.0, 2.7)358/809 (44.3)1.6 (1.3, 1.9)0.523
20060/152 (39.5)2.1 (1.3, 3.3)371/812 (45.7)1.7 (1.4, 2.1)0.674
  1. CI confidence interval, MBS most bothersome symptom, N number of patients in the subgroup of mITT population, n number of patients achieving outcome, PBO placebo
  2. aOdds ratio compared to patients who received placebo in the same subgroup
  3. bInteraction p-value comparing patients using and patients not using migraine preventive medications
\